HiberGen Limited, the Irish genomics company, has announced that it has granted SEQUENOM an exclusive license to produce technology HiberGen developed in mapping the genetic structure of diseases.
The new technology, called SNaPIT,will help develop diagnostic and therapeutic products to improve disease management and radically change the way serious illnesses are treated in the general population.
SEQUENOM, a genomics companybased in California, signed the deal last night, but none of the financial detailshave been made public.
"We are delighted to enter into this new agreement with SEQUENOM, which validates the SNaPIT technology as a rapid and robust genetic variation detection technology," said Dr. Maurice Treacy, Chief Executive of HiberGen.
"SEQUENOM’s reputation as a leader in [genetic] analysis, together with its strong links with academic and research centers make them an ideal partner for HiberGen."
HiberGen will continue to use SNaPIT for its R&D and commercial activities that aim to discover genetic variations of medical importance, with a current focus on rheumatoid arthritis, diabetes and coronary heart disease.